News & Views
Research Focused on CNS Disease
Jan 08 2019 Read 738 Times
Domain Therapeutics (Strasbourg) and Boehringer Ingelheim are collaborating in a multi-target drug discovery and licensing agreement on orphan G Protein-Coupled Receptors (GPCRs) in the Central Nervous System (CNS) disease area.
Domain Therapeutics will use its proprietary platforms, DTect-All™ and bioSens-All™, which enable characterisation of small molecule GPCR binders for the screening of potential lead compounds. Domain will be eligible for an upfront payment, discovery, development and commercial milestone payments as well as royalties on sales. Financial details were not disclosed.
“We are excited to initiate the collaboration with Domain Therapeutics, a leading player in the GPCR space. This collaboration helps us to bolster our CNS research efforts,” said Dr Bernd Sommer, Global Head, CNS Diseases Research at Boehringer Ingelheim. “We have a valuable partner with complementary expertise and key technologies that allow us to accelerate research and development in this area of great unmet medical need.”
“With its focus on emerging science and breakthrough medicines, we are enthusiastic to be working with Boehringer Ingelheim,” said Pascal Neuville, CEO of Domain Therapeutics. “We believe that our approach and technologies will allow for the identification of new drug candidates against these challenging targets and coupled with Boehringer Ingelheim’s strength and expertise, their rapid advancement into the clinic.”
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Export experts talk Corona Virus - Automated cell counting shouldn’t cost the earth Laboratory Products - Spectrophotometer Linearity Validation - Analysi...
View all digital editions
May 31 2020 Houston, TX, USA
May 31 2020 Baltimore, MD, USA
Jun 11 2020 Brussels, Belgium
Jun 20 2020 San Diego, CA, USA
Jun 30 2020 Nuremberg, Germany